Novel, Synthetic DNA Templates Enable Expedited Turnaround Times for mRNA Cancer Vaccines

Time: 2:00 pm
day: Conference Day One


  • mRNA production is limited by availability of high-quality, GMP-grade DNA. Synthetic DNA produced enzymatically can address the drawbacks associated with plasmid derived DNA templates.
  • The use of synthetic DNA templates can greatly reduce the needle-to-needle time in oncology vaccine applications.
  • opDNA is a synthetic DNA template with a 3’ open end, which can feed directly into IVT processes without the need for linearisation.
  • opDNA is devoid of a bacterial backbone and can be designed with long continuous poly-(A) tails encoded within the sequence. opDNA achieves significantly higher mRNA yields, comparable proinflammatory cytokine/chemokine responses, and equivalent gene expression as compared to plasmid derived templates.